Trial Profile
Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs INB-100 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man
- 12 Dec 2023 Results (N=14) containing updated clinical and correlative data from Phase I trial using our recommended phase 2 dose presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 11 Dec 2023 According to an IN8bio media release, the company will host a conference call and webcast tomorrow, Tuesday, December 12, 2023, at 8:30 am ET to review the updated clinical data from this study.
- 11 Dec 2023 According to an IN8bio media release, an additional expansion patient enrollment is on-going and updated data from this study is expected to be presented at medical meetings in 2024.